Csourse Code: Course Title:

Course Instructor:

Academic Task No.: Academic Task Title:

Date of Allotment: Date of submission:

Student’s Roll no: Student’s Reg. no:

Evaluation Parameters:

Learning Outcomes: (Student to write briefly about learnings obtained from the academic tasks)

Declaration:

I declare that this Assignment is my individual work. I have not copied it from any other student’s work
or from any other source except where due acknowledgement is made explicitly in the text, nor has any
part been written for me by any other person.

Student’s Signature:

Evaluator’s comments (For Instructor’s use only)

General Observations Suggestions for Improvement Best part of assignment

Evaluator’s Signature and Date:

Marks Obtained: _______________ Max. Marks: ______________

 RUBRIC

ACC501- ACCOUNTNG FOR MANAGERS

Student Name……………………………… Date………………………….

EVALUATION CRITERIA FAILS TO MEET MEETS EXCEEDS SCORE

EXPECTATIONS EXPECTATIONS EXPECTATIONS
1. COMPANY PROFILE (1 (0 marks) (0.5 marks) (1 mark)
Marks)
Student is not Student is partly Student is updated
-Basic Profile (But not aware of the aware of the about the company
more than one page) company profile company profile profile and initiatives
Prepare the Company and initiatives and initiatives taken and shows
profile of the company taken and shows no taken and shows insights into the
Prepare the basic profile insight into the some insights into functioning of the
of the company (Not more functioning of the the functioning of organization and is
than one page) (1marks) organization. the organization aware of important
policy initiatives and
developments in the
organization
(0-8 marks) (8-16 marks) (16-24 marks)
2. Do the company
analysis through ratios Student is not able Student is partially Student can analyze
a. How the to analyze the ratios able to analyze the the ratios and
company has and interpret the ratios and interpret interpret the position
performed position of the position of of company,
compared to company, including company, including including indications
the last year? indications where indications where where the company
(8 Marks) the company is the company is is lacking
lacking. lacking
Correct data used
Incorrect or Correct data used without any
b. How the inappropriate data with minimal errors, or
company has used for ratio errors; generally assumption(s)
performed calculation; correct comparison made for
compared to incorrect and conclusions unavailable data;
competitors? comparison and drawn. correct
The analysis conclusions drawn. comparison and
is to be done conclusions drawn.
by taking at
least the data
of two
competitors
belonging to
same
industry.
(12 marks)

c. On the basis
information
collected and
analysis
made above,
decide with
 suitable
reasons
whether you
would like to
invest in the
shares of the
company and
why/why
not? (4
marks)
3. Cash Flow analysis (5 (0-2marks) (2-3.5 marks) (3.5-5 marks)
marks)
Analyze company’s cash Student is not able Student is partially Student can compare
position for two years to compare the able to compare the the Cash position of
based on operating, Cash position of Cash position of company based on
investing and financing company based on company based on activities performed
activities and give general activities activities performed
observation for same performed. Correct
Correct company basis of comparison
Inappropriate identified; generally selected and
company selected; correct basis of conclusion drawn.
incorrect basis of comparison
comparison selected and
selected and conclusion drawn.
conclusion drawn.

Scoring:

Below 15= Fails to Meet Expectations.

15-20= Meets Expectations.

20 Above= Exceeds Expectations.

Profile of the Company
Ajanta Pharma Limited (APL) is an multinational company based in India engaged in
development, manufacturing, and marketing of pharmaceutical formulations. It was established
in 1973.

It has a presence in India, the United States, and about 30 other countries in Africa, Asia, Middle
East, and CIS. In these markets, the company serves a wide range of therapeutic products in the
areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine,
multivitamin, gynecology, and pain management. It is driven by innovation-led approach,
execution agility and technological expertise.

Company’s Institutional business comprises of supplies to various government bodies in India

and supply of Anti-Malarial products under WHO approved programs in Africa.

Some of its products are-

Acetaminophen- or paracetamol helps to reduce fever and to relieve a headache with mild to
moderate pain.

Ambroxol- This medication is a mucolytic agent, prescribed for various respiratory diseases
such as emphysema with bronchitis pneumoconiosis, chronic inflammatory pulmonary
conditions, tracheobronchitis (respiratory tract inflammation), bronchiectasis, bronchitis with
bronchospasm asthma.

Clopidogrel-This medication is an anti-platelet agent, that is, a drug that inhibits the ability of
platelets to clump together as part of a blood clot

Cloxacillin- Cloxacillin is used for to the treatment of several infections that may include
endocarditis (infection of the inner layer of the heart),pneumonia (infection of the lung) and
other respiratory tract infections, bone and joint infections, sepsis (blood infection), skin and soft
tissue infections and urinary tract infection.

Febuxostat-This medication is a xanthine oxidase (XO) inhibitor, prescribed for gout and
hyperuricemia (high level of uric acid in blood). It decreases the amount of uric acid in blood.
Mision
There mission is to Serve Global Healthcare needs through Empathy, Innovation and
Technology. We believe that to ensure sustained growth, we need to clearly understand our
customer's needs and use cutting edge technology to present innovative solutions.
Vision
To be a major provider of premium, innovative, yet affordable healthcare products which have
meaningful impact on people’s health and quality of life.
 A.) Liquidity Ratios

1. Current Ratios

Table 1.1 shows comparison between current ratio of Ajanta Pharma with those of Biocon Ltd
and Dr. Reddy’s Lab in the financial year 2017 – 2018.
Competitor1 Competitor 2
Company Ajanta Pharma Biocon Ltd Dr. Reddy’s Lab
Current Ratio 3.65 2.47 1.91

References:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

https://www.moneycontrol.com/financials/biocon/ratiosVI/BL03#BL03

https://www.moneycontrol.com/financials/drreddyslaboratories/ratiosVI/DRL#DRL

Interpretation-

Ajanta Pharma has a current ratio of 3.65:1 which is more than the ideal ratio i.e 2:1 which is not
a satisfactory condition. It means that the company is able to pay off its short terms debts or
obligation and is left with a margin of safety of 2.65 times, as having a Current Assets more than
the Current Liabilities. The company should try to maintain the ideal ratio.

Biocon Ltd has a current ratio of 2.47:1 which is more than the ideal ratio i.e 2:1which is not a
satisfactory condition. It means that the company is able to pay off its short terms debts or
obligation and is left with a margin of safety of 1.47 times, as having a Current Assets more than
the Current Liabilities. The company should try to maintain the ideal ratio.

Dr. Reddy’s Lab has a current ratio of 1.91:1 which is nearly equal to the ideal ratio i.e 2:1,
which is satisfactory condition. It means company is left with the 0.91 times of cushion of safety
after paying its short term debts and obligation. Company is having the appropriate amount of
current Assets required to pay debts within one year but it should try to maintain the ideal ratio.

After comparing the current ratios of all the three companies, it is concluded that the Dr.Reddy
Lab has a most satisfactory ratio as compared to others as it is almost near to the ideal ratio.
Ajanta Pharma has the highest ratio from all of the above, large margin of safety is available with
the company after paying its debts, whereas Biocon also has more than the ideal ratio which
means over utilization of resources is done by these two companies. So they should try to
improve their ratios by decreasing its Current Assets.
2. Quick Ratio
Table 1.2 shows comparison of Quick ratios of Ajanta Pharma with those of Biocon Ltd and Dr. Reddy
Labs as of the financial year 2017 – 2018.

Competitor1 Competitor2
Company Ajanta Pharma Biocon Dr. Reddy’s Lab
Quick Ratio 2.59 1.80 1.52

References-

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

https://www.moneycontrol.com/financials/biocon/ratiosVI/BL03#BL03

https://www.moneycontrol.com/financials/drreddyslaboratories/ratiosVI/DRL#DRL

Interpretation:

Ajanta Pharma has a quick ratio of 2.59:1 which is more than the ideal ratio i.e 1:1.This means
that the company is able to pay off its current liability and is left with the safety of margin of
1.59 times, which is a satisfactory condition. As the company is left with the less amount of
money

Biocon has a quick ratio of 1.8:1 which is more than the ideal ratio i.e 1.1.This This means that
the company is able to pay off its debts due within one year and is left with the safety of margin
of 0.8 times, which is a satisfactory condition it should try to maintain the ideal condition.

Dr. Reddy ‘sLab has a quick ratio of 1.52:1 which is more than the ideal ratio i.e 1:1.This means
that the company has enough current assets to pay off its current liability and is left with a
margin of safety of 0.52 times .Although the ratio is satisfactory but the company should try to
maintain the ideal ratio.

After comparing the quick ratio of all the companies it is concluded that the Ajanta Pharma has a
quick ratio more than the Biocon and Dr. Reddy’s Lab which means that the more safety cushion
is available with the company after paying its short term debts or obligations as compared to the
others. For every 1 current liability, company has 2.59 of quick assets to pay for it. But this much
of quick assets is not a preferable condition so the company should try to maintain the ideal
condition by decreasing its Trade Receivables. Others should also try do the same.
B).Efficiency Ratios

1. Inventory Turnover Ratio

Table 1.3 shows comparison of Inventory Turnover ratios of Ajanta Pharma with those of Biocon
and Dr. Reddy’s Lab as of the financial year 2017 – 2018.

Competitor1 Competitor2
Company Ajanta Pharma Biocon Dr. Reddy’s Lab
Inventory Turnover 5.75 4.31 5.04
Ratio
Inventory 64days 85days 73days
conversion Period

Reference:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

https://www.moneycontrol.com/financials/biocon/ratiosVI/BL03#BL03

https://www.moneycontrol.com/financials/drreddyslaboratories/ratiosVI/DRL#DRL

Interpretation:

Ajanta Pharma has a Inventory Turnover Ratio 5.75 times, which is which is a high turnover
ratio. This means that the company is efficient is managing its stocks, it convert its stock in 64
days into cash. This shows that it is having fast moving stock. Having a good inventory
management. However it should try improve its Inventory Turnover Ratio.

Biocon has a Inventory Turnover Ratio 4.31 times, which is a high turnover ratio. This means
that the company is efficient is managing its stocks, it convert its stock in 85 days into cash. This
shows that it is having fast moving stock. However it should try improve its Inventory Turnover
Ratio.

Dr. Reddy’s has a Inventory Turnover Ratio 5.04 times, which is a high turnover ratio. This
means that the company is efficient in managing its inventory. It converts its stock into cash in
73 days, which shows that it is having fast moving stock because stock is quickly converted into
cash.

After comparing Inventory Turnover Ratios for all the companies, it is concluded that the Ajanta
Pharma is more efficient in the inventory management as it is capable convert its stocks into cash
in just 64 days whereas Biocon take 85 days and Dr. Reddy’s Lab take 73 days to convert. There
they should try to improve its Inventory Turnover Ratio to increase its liquidity.
 2. Debtors Turnover Ratio

Table 1.4 shows comparison of Debtor Turnover ratios of Ajanta Pharma with those of Biocon
and Dr. Reddy Lab as of the financial year 2017 – 2018.

Competitor 1 Competitor2
Company Ajanta Pharma Biocon Dr. Reddy’s Lab
Debtors Turnover 4.57 3.67 2.17
Ratio
Debt collection Period 80 days 99 days 168 days

Reference:

https://capitaline.com/siteFrame.aspx?d=1

Interpretation:

Ajanta Pharma has a Debtors turnover ratio 4.57 times which is a High Turnover Ratio which
means that the company is converting its debtors into cash in 80 days. Relaxation given to the
customers is for the shorter period. This shows that there is prompt payment by the debtors.so the
company can maintain the good liquidity position.

Biocon has a Debtor turnover ratio 3.67 times which is a Low Debtors Turnover Ratio which
means that the company is converting its debtors into cash in 99 days. This means that the
company is not having good credit policy, considering a longer collection period. Debtors is
delaying the payments, as the company is liberal, which results into bad debts for the company

Dr. Reddy’s Lab has a Debtor turnover ratio 2.17 times which is a Low Debtors Turnover Ratio
which means that the company is converting its debtors into cash in 168 days. This means that
the company is not having good credit policy, considering a longer collection period. Debtors is
delaying the payments, as the company is liberal, which results into bad debts for the company.

After comparing the Debtors turnover ratio ,it is concluded that the Ajanta Pharma has a better
ratio than the other as the debtors are paying with in 80 days which is less than the others. So it is
having good repayment policy for its Debtors rather than others. They should also try to maintain
the good ratios.
3.Fixed Asset Turnover Ratio

Table 1.5 shows comparison of Fixed Asset Turnover ratios of Ajanta Pharma with those of Biocon and
Dr. Reddy’s Lab as of the financial year 2017 – 2018.

Competitor1 Competitor2
Company Ajanta Pharma Biocon Dr. Reddy ‘sLab
Fixed Asset 79.64 31.30 54.73
Turnover Ratio

References:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

https://www.moneycontrol.com/financials/biocon/ratiosVI/BL03#BL03

https://www.moneycontrol.com/financials/drreddyslaboratories/ratiosVI/DRL#DRL

Interpretation:

Ajanta Pharma has a fixed turnover ratio of 79.64times which means it is having a high ratio.
The company has a efficient management and proper utilization of Fixed Assets is done for
generating the sales.

Biocon has fixed Turnover Ratio of 31.30 times which is a satisfactory ratio, which means
proper utilization of fixed assets is done for generating the revenues, hence have efficient
management.

Dr. Reddy’s Lab has fixed Turnover Ratio of 54.73 times which is very low, not having the
satisfactory condition. This means company is efficient in management and proper utilization of
Fixed Assets is done for generating the sales.

After comparing the fixed Turnover Ratio for all the three companies, it is concluded that the
Ajanta Pharma is more efficient than the others in generating the profits from its fixed assets.
Thus it is having the more stable financial position than others. Biocon and Dr. Reddy Lab
should try to improve its Fixed Asset Turnover Ratio.
D).Solvency Ratio

1.Debt-Equity Ratio

Table 1.6 shows comparison of Debt to Equity ratio of Ajanta Pharma with those of Biocon and Dr.
Reddy’s Lab as of the financial year 2017 – 2018

Competitor1 Competitor2
Company Ajanta Pharma Biocon Dr. Reddy’s Lab
Debt- Equity Ratio 0.00 0.01 0.22

References-

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

https://www.moneycontrol.com/financials/biocon/ratiosVI/BL03#BL03

https://www.moneycontrol.com/financials/drreddyslaboratories/ratiosVI/DRL#DRL

Interpretation:

Ajanta Pharma has a debt- equity ratio of 0 which means that the company is only raising its
funds from Equity not from Debts. Large margin of safety is available wih the creditors as well
Debt- serving is less burdensome. Company is financially stable.

Biocon Ltd has a debt- equity ratio of 0.01 and Dr. Reddy’s Lab has a 0.22 which is low ratio,
less than the ideal ratio i.e 1:1. This means that company is raising most of its funds rather than
the Debts .It means large margin if safety is available with the creditors. More money is to be
invested in the shareholders.

After comparing the Debt- Equity Ratio for all the three companies it is concluded that the Dr.
Reddy Lab has more ratio than the others. It is dependent on both Debts and Equity for raising
funds. Its is more financial stable than the others. Ajanta Pharma and Dr. Reddy Lab should try
maintain an ideal ratio as increasing the debt can reduce the amount of tax paid.
A.)Profitability Ratios-

1.Gross Profit Ratio

Table 1.7 shows comparison of Gross profit ratio of Ajanta Pharma in the financial year 2017 - 2018 with
that of year 2016 – 2017.

Ajanta Pharma
Year 2018 2017 2016
Gross Profit Ratio 33.95 38.87 38.54

Reference:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

Interpretation:

In the year 2018 Ajanta Pharma has Gross Profit Ratio of 33.95 which means for every Rs 100
sales, cost of production is Rs. 33.95, which means company is having good sales.

In year 2017, it has Gross Profit Ratio of 38.87 which means for every Rs 100 sales, cost of
production is Rs. 38.87, which means company is having good sales.

In the year 2016, it has Gross Profit Ratio of 38.87 which means for every Rs 100 sales, cost of
production is Rs.38.54, which means company is having good sales.

After comparing the Gross Profit Ratio for all the three years, it is concluded that Ajanta Pharma
has highest ratio in 2017 as it has decrease by 5 in 2018 which means company is not improving
according to the past years. Either its selling price has decreased or cost of production has
increased. So less amount cash is available with the company for its expenses. It should try to
improve it.

3.Net Profit Ratio

Table 1.8 shows comparison of Net profit ratio of Ajanta Pharma in the financial year 2017 - 2018 with
that of year 2016 – 2017.

Ajanta Pharma
Year 2018 2017 2016
Net Profit Ratio 9.85 20.06 16.01

References:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22
Interpretation:

In the year 2018, Ajanta Pharma has a Net Profit Ratio of 9.85, which means it is earning Rs
9.85 on the of Rs 100.This is the dividend which is paid to the shareholders. This means
company is profitable as it is earning high and can withstand the adverse conditions.

In the year 2017, company has a Net Profit Ratio of 20.06, which means it is earning Rs 20.06 on
the of Rs 100.This is the dividend which is paid to the shareholders. This means company is
profitable as it is earning high and can withstand the adverse conditions.

In the year 2016, company has Net Profit Ratio of 16.01, which means it is earning Rs 16.01 on
the of Rs 100.This is the dividend which is paid to the shareholders. This means company is
profitable as it is earning high and can withstand the adverse conditions.

After comparing the Net Profit Ratio for the current three years it is concluded that the company
is having its maximum in 2017, after that in 2018 its sales has goes down. So the dividend given
to the shareholders has also decreased. Either its operatingexpenses has increased or income
tax.The company should try to increase its profitability.

3.)Earning per share

Table 1.8 shows comparison of Earning per share of Ajanta Pharma in the financial year 2017 - 2018 with
that of year 2016 – 2017.

Ajanta Pharma
Year 2018 2017 2016
Earning per share 48.59 56.79 47.10

Reference:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

Interpretation:

In the year 2018 Ajanta Pharma has a Earning per share is 48.59, this means that shareholders
will get Rs 48.59 for each share whenever profits are distributed to them.

In the year 2017 it has a Earning per share is 56.79, this means that shareholders will get Rs
56.79 for each share whenever profits are distributed to them. Company has strong financial
position.

In the year 2018 it has a Earning per share is 47.10, this means that shareholders will get Rs
47.10 for each share whenever profits are distributed to them.
After comparing the Net Profit Ratio for the current three years, it is concluded that the company
is having the high ratio in 2017, its profits has decresed by 8.2 which means less amount of
money is also distributed to the shareholders, so the company should try to increase its profits so
that it can become more reliable to invest money in it and attract more shareholders.

4.) Return on assets ratio

Table 1.9 shows comparison of Return on Asset ratio of Ajanta Pharma in the financial year 2017 - 2018
with that of year 2016 – 2017.

Ajanta Pharma
Year 2018 2017 2016
Return on assets 18.65 28.58 29.29
ratio

References:

https://www.moneycontrol.com/financials/ajantapharma/ratiosVI/AP22#AP22

Interpretation:

In the year 2018, Ajanta Pharma has Return on Assets ratio of 18.65 which means upon Rs 100
investment on the asset, company is earning Rs 18.65. The ratio is high which means that the
company is efficient in managing its assets and the generation of profits from it.

In the year 2017, it has Return on Assets ratio of 28.58 which means upon Rs 100 investment on
the asset, company is earning Rs 28.58. The ratio is very high which means that the company is
efficient in managing its assets and the generation of profits from it.The company profitability is
high.

In the year 2016, it has Return on Assets ratio of 29.2 which means upon Rs 100 investment on
the asset, company is earning Rs 29.2. The ratio is very high which means that the company is
efficient in managing its assets and the generation of profits from it.

So after comparing the Return on assets ratio it is concluded that the company is having high
ratio in 2016, and continuously it value is decreasing which means profits earned by the
company is decreasing. It should try to improve its ratio.

INVESTMENT DECISION

The following table 1.11 shows the Dividend per share ratio, Earning per share as well as Price earnings
ratio of Ajanta Pharma compared to those of its competitors as of the financial year 2017 - 2018;
 Company Ajanta Pharma Biocon(Competitor1) Dr. Reddy’s
Lab(Competitor2)
EPS Ratio 48.59 4.04 34.19
Dividened per 0.00 1.00 20.00
share
Market price of 1042.55 635.30 2666.65
share
P/E Ratio 21.4 157.2 78

As the Earning per share given by the Ajanta Pharma is 48.59 which means company has a profit
of Rs 48.59 against share which it will distributed among shareholders.Dividend paids by the
company to the shareholders is zero. Its Price Earning Ratio is 21.4 which means market price of
share of the company is 21.4 times the earnings of the company.

For the Biocon Earning per share is 4.04 which means company has a profit of Rs 4.04 which it
will distribute in the shareholders. Dividend paid to the shareholders is Rs 1 for each share. Its
price Earning Ratio is 157.2 which means market price of share of the company is 78 times the
earning of the company.

For the Dr. Reddy Labs Earning per share is 34.19 which means company has a profits of
Rs.34.19 which it will distribute in the shareholders. Dividends paid to the shareholders is Rs.20
for each share. Its Earning price Ratio is 78 which means market price of share of the company is
78 times the earning of the company.

So After compare to all it is concluded that the Market Price of share of Dr. Reddy Lab is high
than the others, which means after selling of the shares investor can expect more returns and the
dividened given to the shareholders is also more . Its EPS ratio is also satisfactory. I want to
invest in Dr. Reddy Lab.
CASH FLOW STATEMENTS
Interpretation

As of 2018 Ajanta Pharma has inflow of cash from its operating Activities(285.42).Which means
Company is making good sales and generated good profits.For the investing Activities , Outflow
of cash is taking place(260.4) and from the Financing Activities outflow of cash is taking
place(0.20) which means company is using the generated money from operating activities to
purchase fixed assets, Investments and Repayment of loans.

As of 2017, it has Pharma has inflow of cash from its operating Activities (609.2) Which means
Company is making good sales and generated good profits. For the investing Activities , Outflow
of cash is taking place(383.12) and from the Financing Activities outflow of cash is taking
place(201.7) which means company is using the generated money from operating activities to
purchase fixed assets, Investments and Repayment of loans.

After comparing the activities it is concluded that the company has generated less amount of
money in 2018 as compared to 2017 so less money is used to purchase the fixed Assets,
Repayment of loans. Profitability of the company is decreasing so it try to maintain the good
liquidity position.
 ANNEXURE

BALANCE SHEET
Previous Years »
Standalone Balance Sheet ------------------- in Rs. Cr. -------------------
Mar 18 Mar 17 Mar 16 Mar 15 Mar 14

12 mths 12 mths 12 mths 12 mths 12 mths

EQUITIES AND LIABILITIES

SHAREHOLDER'S FUNDS
Equity Share Capital 17.69 17.69 17.69 17.68 17.67
Total Share Capital 17.69 17.69 17.69 17.68 17.67
Reserves and Surplus 1,913.81 1,486.25 1,107.10 768.65 518.65
Total Reserves and Surplus 1,913.81 1,486.25 1,107.10 768.65 518.65
Total Shareholders Funds 1,931.50 1,503.94 1,124.79 786.33 536.32
NON-CURRENT LIABILITIES
Long Term Borrowings 0.00 0.00 13.82 32.27 51.28
Deferred Tax Liabilities [Net] 47.00 27.38 20.11 15.16 22.98
Other Long Term Liabilities 0.00 1.83 0.46 2.50 2.50
Long Term Provisions 13.16 3.15 2.59 4.76 2.83
Total Non-Current Liabilities 60.16 32.36 36.98 54.69 79.59
CURRENT LIABILITIES
Short Term Borrowings 0.00 0.00 46.05 17.90 60.54
Trade Payables 211.47 145.31 145.04 108.12 110.90
Other Current Liabilities 71.73 54.13 50.68 54.51 49.81
Short Term Provisions 16.99 12.80 11.36 64.30 42.71
Total Current Liabilities 300.19 212.24 253.13 244.83 263.96
Total Capital And Liabilities 2,291.85 1,748.54 1,414.90 1,085.85 879.87
ASSETS
NON-CURRENT ASSETS
Tangible Assets 1,029.29 566.97 429.08 268.16 260.02
Intangible Assets 7.40 5.96 3.75 3.16 1.38
Capital Work-In-Progress 61.33 338.03 238.42 170.20 93.55
Intangible Assets Under Development 0.00 1.23 1.38 0.00 0.00
Fixed Assets 1,098.02 912.19 672.63 441.52 354.95
Non-Current Investments 18.26 17.26 17.25 57.16 23.84
Long Term Loans And Advances 0.00 0.00 21.11 8.87 38.68
Other Non-Current Assets 80.56 44.02 4.27 5.27 8.75
Total Non-Current Assets 1,196.84 973.47 715.26 512.82 426.22
CURRENT ASSETS
Current Investments 182.38 181.56 66.39 19.46 55.00
Inventories 317.37 179.28 189.78 153.05 148.77
Trade Receivables 464.42 336.00 350.48 240.85 177.09
Cash And Cash Equivalents 38.67 22.84 33.02 105.69 29.08
Short Term Loans And Advances 0.00 0.00 59.24 45.04 43.09
OtherCurrentAssets 92.17 55.39 0.73 8.94 0.62
Total Current Assets 1,095.01 775.07 699.64 573.03 453.65
Total Assets 2,291.85 1,748.54 1,414.90 1,085.85 879.87
OTHER ADDITIONAL INFORMATION
CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities 173.65 146.19 123.97 16.15 51.33
CIF VALUE OF IMPORTS
Raw Materials 0.00 0.00 29.77 49.65 30.00
Stores, Spares And Loose Tools 0.00 0.00 1.82 0.67 0.00
Trade/Other Goods 0.00 0.00 0.00 0.00 0.30
Capital Goods 0.00 0.00 72.17 14.96 29.88
EXPENDITURE IN FOREIGN EXCHANGE
Expenditure In Foreign Currency 161.55 220.58 64.06 59.43 56.61
REMITTANCES IN FOREIGN CURRENCIES FOR
DIVIDENDS
Dividend Remittance In Foreign Currency - - 0.63 0.10 0.37
EARNINGS IN FOREIGN EXCHANGE
FOB Value Of Goods - - 952.71 806.20 660.56
Other Earnings 1,166.73 1,147.70 89.47 43.23 29.01
BONUS DETAILS
Bonus Equity Share Capital 7.09 7.09 7.09 7.09 7.09
NON-CURRENT INVESTMENTS
Non-Current Investments Quoted Market
- - - 45.35 -
Value
Non-Current Investments Unquoted Book
18.26 17.26 24.20 24.07 23.84
Value
CURRENT INVESTMENTS
Current Investments Quoted Market Value - - 76.78 19.89 56.98
181.56
Current Investments Unquoted Book Value 182.38
PROFIT AND LOSS STATEMENT

Ajanta Pharma Previous Years »

Standalone Profit & Loss account ------------------- in Rs. Cr. -------------------
Mar 18 Mar 17 Mar 16 Mar 15 Mar 14

12 mths 12 mths 12 mths 12 mths 12 mths

INCOME
Revenue From Operations [Gross] 1,762.69 1,753.68 1,544.65 1,340.27 1,087.52
Less: Excise/Sevice Tax/Other Levies 5.10 18.38 15.39 11.65 7.65
Revenue From Operations [Net] 1,757.59 1,735.30 1,529.26 1,328.62 1,079.87
Other Operating Revenues 67.76 69.03 22.50 27.58 30.05
Total Operating Revenues 1,825.35 1,804.33 1,551.76 1,356.20 1,109.92
Other Income 73.01 66.95 82.35 33.70 17.72
Total Revenue 1,898.36 1,871.28 1,634.11 1,389.90 1,127.64
EXPENSES
Cost Of Materials Consumed 375.43 373.31 397.21 321.18 299.87
Purchase Of Stock-In Trade 73.01 59.23 57.81 50.21 40.67
Changes In Inventories Of FG,WIP And
-49.15 7.29 -41.02 9.22 7.14
Stock-In Trade
Employee Benefit Expenses 342.89 269.78 235.38 186.34 147.25
Finance Costs 0.24 1.24 4.20 5.01 8.22
Depreciation And Amortisation Expenses 57.14 59.48 42.68 49.42 41.97
Other Expenses 536.36 460.30 386.53 316.69 269.46
Total Expenses 1,335.92 1,230.63 1,082.79 938.07 814.58
Mar 18 Mar 17 Mar 16 Mar 15 Mar 14

12 mths 12 mths 12 mths 12 mths 12 mths

Profit/Loss Before Exceptional,

562.44 640.65 551.32 451.83 313.06
ExtraOrdinary Items And Tax
Exceptional Items 0.00 0.00 0.00 -6.95 0.00
Profit/Loss Before Tax 562.44 640.65 551.32 444.88 313.06
Tax Expenses-Continued Operations
Current Tax 114.60 136.98 134.92 145.21 83.58
Less: MAT Credit Entitlement 0.00 0.00 0.00 0.00 -9.84
Deferred Tax 20.32 3.86 4.95 -7.24 -0.67
Tax For Earlier Years 0.00 0.00 -3.03 0.54 -0.55
Total Tax Expenses 134.92 140.84 136.84 138.51 92.20
Profit/Loss After Tax And Before
427.52 499.81 414.48 306.37 220.86
ExtraOrdinary Items
Profit/Loss From Continuing Operations 427.52 499.81 414.48 306.37 220.86
Profit/Loss For The Period 427.52 499.81 414.48 306.37 220.86
Mar 18 Mar 17 Mar 16 Mar 15 Mar 14

12 mths 12 mths 12 mths 12 mths 12 mths

OTHER ADDITIONAL INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.) 48.59 56.79 47.10 34.84 62.83
Diluted EPS (Rs.) 48.58 56.78 47.10 34.80 62.72
VALUE OF IMPORTED AND INDIGENIOUS RAW
MATERIALS
Imported Raw Materials 0.00 0.00 26.08 50.38 33.81
Indigenous Raw Materials 0.00 0.00 371.13 270.80 266.06
STORES, SPARES AND LOOSE TOOLS
Imported Stores And Spares 0.00 0.00 1.82 0.67 0.00
Indigenous Stores And Spares 0.00 0.00 34.36 20.43 14.43
DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend 0.00 114.41 70.40 52.82 35.18
Tax On Dividend 0.00 14.49 6.15 5.69 5.98
Equity Dividend Rate (%) 0.00 650.00 400.00 300.00 200.00

Source : Dion Global Solutions Limited